ORION CORPORATION

The neurodegenerative disorder therapeutics market is projected to grow from $18.53 billion in 2023 to $28.33 billion in 2028 at a CAGR of 9.0%, driven by factors like aging population, rising prevalence of neurodegenerative disorders, and strategic collaborations among pharmaceutical companies.

Avenacy launches Dexmedetomidine Injection, USP, a therapeutic generic equivalent for Precedex®, indicated for sedation in ICU and surgical settings. Available in 200 mcg/2 mL vials, it features enhanced packaging for accurate medication selection. U.S. sales for the product were $19 million in the past year.

Depixus launches MAGNA One for biomolecular interaction analysis, PacBio reduces HiFi human genome sequencing cost to under $500, Jackson Laboratory and Allentown partner for remote mouse monitoring, PumasAI releases AI tools for healthcare data analysis, VALANX Biotech and Fina Biosolutions collaborate on conjugate vaccine development, iotaSciences validates isoPick™ platform for single-cell lipidomics, CalciMedica raises $10.2M in public offering, Biosynth opens new site in Suzhou, Orion Corporation halts ODM-111 development, Innomost appoints Tiina Bensky as CEO, and PLL Therapeutics names Souad Kechairi as Chief Medical Officer.

Bayer submits application to EMA for darolutamide, an oral ARi, in combination with ADT for metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide, already approved in mHSPC and nmCRPC, aims to extend survival and delay disease progression while maintaining daily living. Phase III ARANOTE trial results show significant reduction in radiological progression or death risk by 46% compared to placebo plus ADT. Darolutamide, developed jointly by Bayer and Orion Corporation, exhibits strong antagonistic activity against the androgen receptor, minimizing side effects.

Darolutamide plus ADT for mHSPC submitted to EMA; ARANOTE trial showed 46% reduction in risk of radiological progression or death, with 24-month rPFS rates of 70.3% vs 52.1% for placebo. Bayer seeks to expand darolutamide's indication to include mHSPC patients.

Bayer AG submits application to EMA for darolutamide, an oral ARi, in combination with ADT for metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide, marketed as Nubeqa, is already approved in over 80 markets for mHSPC and in more than 85 countries for non-metastatic castration-resistant prostate cancer (nmCRPC). Phase III ARANOTE trial results show significant reduction in radiological progression or death risk with darolutamide plus ADT compared to placebo plus ADT.

Bayer submits application to EMA for darolutamide, seeking approval for use with ADT in mHSPC patients, based on ARANOTE trial results. Darolutamide, jointly developed by Orion and Bayer, is already approved in mHSPC and nmCRPC.

Bayer submits application to EMA for darolutamide, an oral androgen receptor inhibitor, for use with ADT in metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide, already approved in mHSPC and nmCRPC, showed significant reduction in radiological progression or death risk in the ARANOTE trial.

Bayer submits sNDA to FDA for NUBEQA in combination with ADT for mHSPC, aiming to expand its use beyond current indications.

Bayer submits sNDA to FDA for darolutamide in mHSPC, based on ARANOTE trial results. Darolutamide, co-developed by Orion and Bayer, is already approved in mHSPC and nmCRPC. Nubeqa sales exceeded €1 billion in 2024, marking a milestone for Orion.